2 papers indexed here
We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.
Not the right person? Other researchers publish under this name.
E. Zucca, Bayer Bms Cellestia Incyte Astra Zeneca, Loxo Oncology et al.
· 0 citations
BTK/BCL2 dual targeting enhances apoptosis in marginal zone lymphoma: preclinical activity of tacabrutideg (BGB-16673) and sonrotoclax.
Tacabrutideg demonstrates potent preclinical activity in MZL as a single agent and in combination regimens, and together with the superior activity of sonrotoclax, these findings provide a strong rationale for the clinical evaluation of dual BTK degradation and BCL2 inhibition in patients with MZL.
A. Arribas, Alex Zadro, E. Civanelli et al.
· Haematologica · 0 citations